NFE2L2 and diabetes mellitus: Treatment with HSP90 inhibitor can restrict macrophage inflammation and protect from diabetes-associated atherosclerosis via induction of nuclear factor erythroid-derived 2-like 2 (Nrf2) and concomitant inhibition of nuclear factor kappa B (NF-κB)-dependent cytoprotective mechanisms [54].